Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Bucillamine, cysteine derivative is oral anti-inflammatory drug under investigation to treat adults with COVID-19 in outpatient setting and has to mitigate effects of proinflammatory reactive oxygen species and prevent acute lung injury during respiratory infections.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
Appili to present update on topical formulation of paromomycin, ATI-1801 already shown to be safe and effective against the disfiguring disease, cutaneous leishmaniasis, in Phase 3 study.
Lead Product(s): Paromomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1801
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
The net proceeds of the Offering will be used primarily for working capital purposes and to fund the development of certain product candidates including ATI-1801 (paromomycin) of the Company.
Lead Product(s): Paromomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1801
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Bloom Burton Securities
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 18, 2022
Details:
The net proceeds of the Offering will be used primarily for working capital purposes and to fund the development of certain product candidates of the Company. Details as to the specific allocation of the proceeds will be disclosed in the Prospectus Supplement.
Lead Product(s): Paromomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1801
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Bloom Burton Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering May 17, 2022
Details:
Bucillamine, (N-(mercapto-2-methylpropionyl)-l-cysteine) an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
RVX-208 (apabetalone), is first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 selective BET inhibitor that works in preventing and treating disease progression by regulating expression of disease-causing genes.
Lead Product(s): Apabetalone
Therapeutic Area: Infections and Infectious Diseases Product Name: RVX-208
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Article described, antibody level were significantly lower in group treated with TNF inhibitor with methotrexate, abatacept, mycophenolate mofetil , MMF or mizoribine combined with calcineurin inhibitor, and rituximab or cyclophosphamide compared to those with Bucillamine.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2022
Details:
The study met its primary endpoint, with ATI-1801 administered topically once daily for 20 days demonstrating a significant improvement in the rate of clinical cure of the index lesion compared to vehicle (82% vs 58%; p-value < 0.001).
Lead Product(s): Paromomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1801
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of the RESOLUTION study with LAU-7b in hospitalized moderate-to-severe COVID-19 patients.
Lead Product(s): Fenretinide
Therapeutic Area: Infections and Infectious Diseases Product Name: LAU-7b
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
701 subjects dosed to date in Phase 3 trial of Bucillamine, an oral drug with anti-inflammatory and antiviral properties is on-track to complete study enrollment in Q1-2022 and FDA submission thereafter.
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Delta Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2022
